Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Clinical trial NCT03277248 · COMPLETED
Trial details
- NCT number
- NCT03277248
- Sponsor
- TG Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-25
- Primary completion
- 2020-08-04
- Enrollment
- 545
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.